Payment Policy | Radiopharmaceuticals



EFFECTIVE DATE: 10 | 20 | 2009

POLICY LAST UPDATED: 02 | 16 | 2016

OVERVIEW

This is a reimbursement policy to document coverage of radiopharmaceuticals.

MEDICAL CRITERIA

Not applicable

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

BlueCHiP for Medicare and Commercial Products

Radiopharmaceuticals are covered if used as part of a covered service.

COVERAGE

Benefits may vary between groups/contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for diagnostic imaging, lab, and machine tests coverage/benefits.

BACKGROUND

Radiopharmaceuticals are drugs that contain radioactive materials called *radioisotopes*. They may be put into a vein, taken by mouth, or placed in a body cavity. Depending on the drug and how it's given, these materials travel to various parts of the body to treat cancer or relieve its symptoms. They put out radiation, mostly in the form of alpha and beta particles that target the affected areas. They're most often used in small amounts for imaging tests, but larger doses can be used to deliver radiation.

CODING

BlueCHiP for Medicare and Commercial Products

The following diagnostic radiopharmaceuticals are covered if used as part of a covered service:

- Professional Providers: If covered; service is separately reimbursed
- Institutional Providers: If covered; service is not separately reimbursed

A9500	A9501	A9502	A9503	A9504	A9505
A9507	A9508	A9509	A9510	A9512	A9515* A9516
A9520	A9521	A9524	A9528	A9529	A9531
A9532	A9536	A9537	A9538	A9539	A9540
A9541	A9542	A9544	A9546	A9547	A9548
A9550	A9551	A9553	A9554	A9556	A9557
A9558	A9559	A9560	A9561	A9562	A9566
A9567	A9568	A9569	A9570	A9571	A9572
A9575	A9576	A9577	A9578	A9579	A9581
A9582	A9583	A9584	A9585	A9587*	A9588*

For the following services, please follow the unlisted procedures process:

A9597* A9598*

*New codes effective 1/1/2017

The following radiopharmaceuticals are **covered** but **not separately reimbursed** for both professional and institutional providers:

A9526 A9552 A9555 A9580

The following therapeutic radiopharmaceuticals are covered and separately reimbursed for both professional and institutional providers:

A9517 A9527 A9530 A9543 A9545 A9563 A9564 A9600 A9604

For the following diagnostic radiopharmaceuticals, refer to the separate medical policy for Beta Amyloid Imaging with Positron Emission Tomography for Alzheimer Disease for coverage details (See Related Policies section):

A9586 A9599

For the following therapeutic radiopharmaceutical, refer to the separate medical policy for Radium-223, Xofigo for Treatment of Metastatic, Castration-Resistant Prostate Cancer for coverage criteria (See Related Policies section):

A9606

For the following diagnostic radiopharmaceutical, refer to the separate policy for Dopamine Transporter Imaging with Single-Photon Emission Computed Tomography (DAT-SPECT) (See Related Policies section) A9584

RELATED POLICIES

Unlisted Procedures

Beta Amyloid Imaging With Positron Emission Tomography for Alzheimer Disease Radium-223, Xofigo; for Treatment of Metastatic, Castration-Resistant Prostate Cancer Dopamine Transporter Imaging With Single-Photon Emission Computed Tomography (DAT-SPECT)

PUBLISHED

Provider Update, April 2016 Provider Update, December 2009

REFERENCES

None

----- CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.